{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:11:54Z","timestamp":1790154714459,"version":"4.0.1"},"reference-count":26,"publisher":"Walter de Gruyter GmbH","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Psoriasis is a chronic systemic inflammatory disease, frequently associated with metabolic comorbidities that may influence therapeutic outcomes. Real-world evidence on the effectiveness of biologic therapy in this complex clinical context remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the prevalence of comorbidities in patients with psoriasis receiving biologic therapy and to identify factors associated with treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective observational study including 121 patients with chronic plaque psoriasis. Demographic data, comorbidities, biologic treatment class, and PASI\/DLQI evolution at baseline and at standardized 6 and 12 months assessments was analyzed, together with the latest available clinical assessment recorded in 2025 after variable treatment durations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Comorbidities were present in 84.3% of patients, most frequently hepatic steatosis (73.6%), obesity (45.5%), hypertension (41.3%), and diabetes (19%). A significant improvement in PASI and DLQI scores was observed at all follow-up points (p &lt; 0.001). Complete skin clearance (PASI 100) was achieved by 18.1% of the patients at 6 months and by 44.6% at 12 months. In multivariable logistic regression analysis, lower PASI scores at six months were independently associated with a higher likelihood of achieving PASI 100 at one year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Biologic therapy was associated with marked clinical and quality-of-life improvement. Although metabolic comorbidities were highly prevalent, no significant association between metabolic comorbidities and PASI 100 response at one year was identified in the analyses performed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/rjim-2026-0020","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:57:18Z","timestamp":1790153838000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Effectiveness of Biologic Therapy in Patients with Psoriasis: Metabolic Comorbidities and Treatment Outcomes"],"prefix":"10.2478","author":[{"given":"Adelina F.","family":"Ghilencea","sequence":"first","affiliation":[{"name":"Carol Davila University of Medicine and Pharmacy Doctoral School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel O.","family":"Costache","sequence":"additional","affiliation":[{"name":"Dermatology 2 Discipline , Carol Davila University of Medicine and Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"C\u0103runtu","sequence":"additional","affiliation":[{"name":"Physiology Department , Carol Davila University of Medicine and Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Scheau","sequence":"additional","affiliation":[{"name":"Physiology Department , Carol Davila University of Medicine and Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilinca","family":"Savulescu-Fiedler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Carol Davila University of Medicine and Pharmacy ; Department of Internal Medicine, Coltea Clinical Hospital , Bucharest"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Dicu-Andreescu","sequence":"additional","affiliation":[{"name":"SC. \u201cDr. Irimia\u201d SRL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Cojocaru","sequence":"additional","affiliation":[{"name":"Bucharest Emergency University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca S.","family":"Costache","sequence":"additional","affiliation":[{"name":"Internal Medicine and Gastroenterology Department , Carol Davila University of Medicine and Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026092308570970657_j_rjim-2026-0020_ref_001","doi-asserted-by":"crossref","unstructured":"SKAYEM C., TAIEB C., HALIOUA B., BAISSAC C., SAINT AROMAN M. Epidemiology of Psoriasis: A Worldwide Global Study. Acta Derm Venereol. 2025;105:adv42945.","DOI":"10.2340\/actadv.v105.42945"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_002","doi-asserted-by":"crossref","unstructured":"UNTAAVEESUP S., KANTAGOWIT P., UNGPRASERT P., KITLERTBANCHONG N., VAJIRAVIROJ T., SUTITHAVINKUL T., et al. The Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease in Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis. J Clin Med. 2025;14(4):1374.","DOI":"10.3390\/jcm14041374"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_003","doi-asserted-by":"crossref","unstructured":"PARISI R., ISKANDAR IYK., KONTOPANTELIS E., AUGUSTIN M., GRIFFITHS CEM., ASHCROFT DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.","DOI":"10.1136\/bmj.m1590"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_004","doi-asserted-by":"crossref","unstructured":"GRIFFITHS CEM., ARMSTRONG AW., GUDJONSSON JE., BARKER JNWN. Psoriasis. Lancet. 2021;397(10281):1301\u201315.","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_005","doi-asserted-by":"crossref","unstructured":"COSTACHE DO., FEROIU O., GHILENCEA A., GEORGESCU M., C\u0102RUNTU A., C\u0102RUNTU C., et al. Skin Inflammation Modulation via TNF-\u03b1, IL-17, and IL-12 Family Inhibitors Therapy and Cancer Control in Patients with Psoriasis. Int J Mol Sci. 2022;23(9):5198.","DOI":"10.3390\/ijms23095198"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_006","doi-asserted-by":"crossref","unstructured":"COSTACHE D., BLEJAN H., POENARU M., COSTACHE R. Skin Cancer Correlations in Psoriatic Patients. Cancers (Basel). 2023;15(9):2451.","DOI":"10.3390\/cancers15092451"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_007","unstructured":"GHILENCEA A., BLEJAN H., COSTACHE D., ENACHE A., CARUNTU C., SCHEAU C. Immunomodulatory Treatment Strategies in Psoriasis Patients with High-Risk Systemic Comorbidities: A Narrative Review and Case Series. Rom J Mil Med. 2026;CXXIX(3)."},{"key":"2026092308570970657_j_rjim-2026-0020_ref_008","doi-asserted-by":"crossref","unstructured":"BOEHNCKE WH., SCH\u00d6N MP. Psoriasis. Lancet. 2015;386(9997):983\u201394.","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_009","doi-asserted-by":"crossref","unstructured":"ARMSTRONG AW., READ C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis. JAMA. 2020;323(19):1945.","DOI":"10.1001\/jama.2020.4006"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_010","doi-asserted-by":"crossref","unstructured":"GISONDI P., TARGHER G., ZOPPINI G., GIROLOMONI G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):758\u201364.","DOI":"10.1016\/j.jhep.2009.04.020"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_011","doi-asserted-by":"crossref","unstructured":"COSTACHE RS., GEORGESCU M., GHILENCEA A., FEROIU O., TIPLICA SG., COSTACHE DO. The Role of Inflammation in the Pathogenesis of Psoriasis. Rom J Mil Med. 2023;126(3):245\u201353.","DOI":"10.55453\/rjmm.2023.126.3.2"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_012","doi-asserted-by":"crossref","unstructured":"GHILENCEA AF., COJOCARU DL., POENARU M., COSTACHE RS., COSTACHE DO., CARUNTU C. The Effect of Biological Therapies on Psoriasis and Its Associated Comorbidities \u2013 New Facts and Future Options. Rom J Mil Med. 2025;128(4):318\u201324.","DOI":"10.55453\/rjmm.2025.128.4.6"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_013","doi-asserted-by":"crossref","unstructured":"COSTACHE D., BLEJAN H., COJOCARU D., IONI\u021a\u0102 G., POENARU M., CONSTANTIN M., et al. Intersecting Pathways: Nonalcoholic Fatty Liver Disease and Psoriasis Duet\u2014A Comprehensive Review. Int J Mol Sci. 2024;25(5):2660.","DOI":"10.3390\/ijms25052660"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_014","doi-asserted-by":"crossref","unstructured":"CANDIA R., RUIZ A., TORRES-ROBLES R., CH\u00c1VEZ-TAPIA N., M\u00c9NDEZ-S\u00c1NCHEZ N., ARRESE M. Risk of non-alcoholic fatty liver disease in  patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29(4):656\u201362.","DOI":"10.1111\/jdv.12847"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_015","doi-asserted-by":"crossref","unstructured":"JAMES L., DIAMOND C., AL-MOSSAWI H., ANDERSSON A., PANDYA P., SHUMBAYAWONDA E., et al. High prevalence of MASLD in psoriasis and psoriatic arthritis assessed with multiparametric magnetic resonance imaging. Rheumatology. 2025;64(11):5741\u201350.","DOI":"10.1093\/rheumatology\/keaf344"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_016","doi-asserted-by":"crossref","unstructured":"DONS M., N\u00c4SLUND-KOCH C., SENGEL\u00d8V M., B\u00d8GH-S\u00d8RENSEN S., SKAARUP KG., L\u00d8VENDORF MB., et al. Metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk factors, and cardiac manifestations in psoriasis: A cross-sectional study of 255 patients. J Intern Med. 2026;299(2):283\u201399.","DOI":"10.1111\/joim.70053"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_017","doi-asserted-by":"crossref","unstructured":"BUZZETTI E., PINZANI M., TSOCHATZIS EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038\u201348.","DOI":"10.1016\/j.metabol.2015.12.012"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_018","doi-asserted-by":"crossref","unstructured":"TILG H., MOSCHEN AR. Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis. Hepatology. 2010;52(5):1836\u201346.","DOI":"10.1002\/hep.24001"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_019","doi-asserted-by":"crossref","unstructured":"EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. Corrigendum to \u201cEASL recommendations on treatment of hepatitis C: Final update of the series\u201d [J Hepatol 73 (2020) 1170\u20131218]. J Hepatol. 2023;78(2):452.","DOI":"10.1016\/j.jhep.2022.10.006"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_020","doi-asserted-by":"crossref","unstructured":"MENTER A., STROBER BE., KAPLAN DH., KIVELEVITCH D., PRATER EF., STOFF B., et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372.","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_021","doi-asserted-by":"crossref","unstructured":"MEHTA NN., AZFAR RS., SHIN DB., NEIMANN AL., TROXEL AB., GELFAND JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000\u20136.","DOI":"10.1093\/eurheartj\/ehp567"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_022","doi-asserted-by":"crossref","unstructured":"EGEBERG A., ROSEN\u00d8 NAL., THEIN D., L\u00d8RUP EH., NIELSEN ML., NYMAND L., et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53:151979.","DOI":"10.1016\/j.semarthrit.2022.151979"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_023","doi-asserted-by":"crossref","unstructured":"WARREN RB., SMITH CH., YIU ZZN., ASHCROFT DM., BARKER JNWN., BURDEN AD., et al. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632\u201340.","DOI":"10.1038\/jid.2015.208"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_024","doi-asserted-by":"crossref","unstructured":"DING Q., PUIG L., FAN T., SMITH N. Predictors of biologic treatment of psoriasis: a non-interventional study. Clin Outcomes Res. 2014;6:93.","DOI":"10.2147\/CEOR.S54797"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_025","doi-asserted-by":"crossref","unstructured":"BAI F., LI GG., LIU Q., NIU X., LI R., MA H. Short-Term Efficacy and Safety of IL-17, IL-12\/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. J Immunol Res. 2019;2019:1\u201325.","DOI":"10.1155\/2019\/2546161"},{"key":"2026092308570970657_j_rjim-2026-0020_ref_026","doi-asserted-by":"crossref","unstructured":"ZHOU XD., CAI J., TARGHER G., BYRNE CD., SHAPIRO MD., SUNG KC., et al. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol. 2022;21(1):270.","DOI":"10.1186\/s12933-022-01697-0"}],"container-title":["Romanian Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/rjim-2026-0020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:57:35Z","timestamp":1790153855000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/rjim-2026-0020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":26,"alternative-id":["10.2478\/rjim-2026-0020"],"URL":"https:\/\/doi.org\/10.2478\/rjim-2026-0020","relation":{},"ISSN":["2501-062X"],"issn-type":[{"value":"2501-062X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}